Advertisement
Advertisement
JUNS
Jupiter Neurosciences, Inc. Common Stock
0.36
USDSponsored
+0.02
+4.29%
Apr 08, 10:10 UTC -4
Open
JUNS Earnings Reports
Positive Surprise Ratio
JUNS beat 3 of 5 last estimates.
60%
Next Report
Date of Next Report
--
Estimate for Q-- -- (Revenue/ EPS)
--
/--
Implied change from Q4 25 (Revenue/ EPS)
--
/--
Implied change from Q-- -- (Revenue/ EPS)
--
/--
Jupiter Neurosciences, Inc. Common Stock earnings per share and revenue
On Apr 01, 2026, JUNS reported earnings of -0.06 USD per share (EPS) for Q4 25, beating the estimate of -0.07 USD, resulting in a 6.16% surprise. Revenue reached 22.00 thousand, compared to an expected 76.50 thousand, with a -71.24% difference. The market reacted with a -2.90% price change (close before vs. close after earnings).
Looking ahead to -- --, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Actinium Pharmaceuticals, Inc
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$0.19
Actual
-$0.20
Surprise
-5.04%
Scienture Holdings, Inc. Common Stock
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$0.28
Actual
-$0.11
Surprise
+61.48%
Reviva Pharmaceuticals Holdings, Inc. Common Stock
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$1.19
Actual
-Surprise
-
60 Degrees Pharmaceuticals, Inc. Common Stock
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$2.32
Actual
-$2.34
Surprise
-0.62%
Galmed Pharmaceuticals Ltd.
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.52
Actual
-$0.80
Surprise
-53.79%
Centessa Pharmaceuticals plc - ADR
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.38
Actual
-$0.48
Surprise
-23.58%
Lexeo Therapeutics, Inc. Common Stock
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$0.32
Actual
-$0.27
Surprise
+15.84%
Galectin Therapeutics Inc.
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.10
Actual
-$0.08
Surprise
+21.57%
Unicycive Therapeutics, Inc. Common Stock
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$0.48
Actual
-$0.81
Surprise
-69.64%
Cardiol Therapeutics Inc. Class A Common Shares
Report Date
Apr 01, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.07
Surprise
+14.22%
FAQ
What were Jupiter Neurosciences, Inc. Common Stock's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Jupiter Neurosciences, Inc. Common Stock reported EPS of -$0.06, beating estimates by 6.16%, and revenue of $22.00K, -71.24% below expectations.
How did the market react to Jupiter Neurosciences, Inc. Common Stock's Q4 2025 earnings?
The stock price moved down -2.9%, changed from $0.38 before the earnings release to $0.37 the day after.
When is Jupiter Neurosciences, Inc. Common Stock expected to report next?
The next earning report is scheduled for --.
What are the forecasts for Jupiter Neurosciences, Inc. Common Stock's next earnings report?
Based on --
analysts, Jupiter Neurosciences, Inc. Common Stock is expected to report EPS of -- and revenue of -- for Q-- --.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement